Literature DB >> 27208634

Efficiency of interleukin 6 and interferon gamma in the differentiation of invasive pulmonary aspergillosis and pneumocystis pneumonia in pediatric oncology patients.

He-Ping Shen1, Yong-Min Tang2, Hua Song1, Wei-Qun Xu1, Shi-Long Yang1, Xiao-Jun Xu3.   

Abstract

OBJECTIVE: Invasive pulmonary aspergillosis (IPA) and Pneumocystis pneumonia (PCP) are two types of pulmonary fungal infection that are not easy to differentiate. The purpose of this study was to investigate the role of inflammatory cytokines in the differential diagnosis of IPA and PCP.
METHODS: A total of 227 pediatric oncology patients diagnosed with acute pneumonia were enrolled. They were divided into three groups: IPA, PCP, and 'others'. The cytokine levels in these groups were compared, including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-10, IL-6, IL-4, and IL-2.
RESULTS: Of the six cytokines, only IL-6 and IFN-γ levels were elevated in patients with acute pneumonia. IL-6 was comparable between patients with IPA and PCP (52.0 pg/ml vs. 25.8 pg/ml, p=0.092), while IFN-γ was much higher in patients with PCP (19.9 pg/ml vs. 8.9 pg/ml, p=0.001). The accuracy of IL-6 and the ratio of IL-6/IFN-γ in predicting IPA were 69.0% and 72.0%, respectively, while the accuracy of IFN-γ to predict PCP was 67.2%. IL-6 >140 pg/ml and IL-6/IFN-γ >9.0 presented specificities of 90% in predicting IPA, while IFN-γ >40 pg/ml presented specificity of 90% in predicting PCP.
CONCLUSIONS: IL-6 is predominantly elevated in IPA, while IFN-γ is significantly increased in PCP. These are helpful tools for the differential diagnosis of IPA and PCP.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cytokine; Interferon gamma; Interleukin 6; Invasive pulmonary aspergillosis; Oncology; Pneumocystis pneumonia

Mesh:

Substances:

Year:  2016        PMID: 27208634     DOI: 10.1016/j.ijid.2016.05.016

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Authors:  Zoe Oesterreicher; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-08-01       Impact factor: 3.553

2.  Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples.

Authors:  Sven Heldt; Juergen Prattes; Susanne Eigl; Birgit Spiess; Holger Flick; Jasmin Rabensteiner; Gemma Johnson; Florian Prüller; Albert Wölfler; Tobias Niedrist; Tobias Boch; Peter Neumeister; Heimo Strohmaier; Robert Krause; Dieter Buchheidt; Martin Hoenigl
Journal:  J Infect       Date:  2018-07-01       Impact factor: 6.072

3.  Evaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients.

Authors:  Samuel M Gonçalves; Katrien Lagrou; Cláudia S Rodrigues; Cláudia F Campos; Leticia Bernal-Martínez; Fernando Rodrigues; Ricardo Silvestre; Laura Alcazar-Fuoli; Johan A Maertens; Cristina Cunha; Agostinho Carvalho
Journal:  Front Microbiol       Date:  2017-11-29       Impact factor: 5.640

4.  Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation.

Authors:  Ian F J Pirker; Jacqueline Krane-Nuber; Werner C Albrich; Rüdiger Müller; Thomas Neumann
Journal:  BMC Rheumatol       Date:  2018-11-03

5.  Integration of Interleukin-6 Improves the Diagnostic Precision of Metagenomic Next-Generation Sequencing for Infection in Immunocompromised Children.

Authors:  Di Wang; Min Lai; Hua Song; Jing-Ying Zhang; Fen-Ying Zhao; Juan Liang; Wei-Qun Xu; Yong-Min Tang; Xiao-Jun Xu
Journal:  Front Microbiol       Date:  2022-03-08       Impact factor: 5.640

Review 6.  COVID-19 associated with pulmonary aspergillosis: A literature review.

Authors:  Chih-Cheng Lai; Weng-Liang Yu
Journal:  J Microbiol Immunol Infect       Date:  2020-09-24       Impact factor: 4.399

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.